All patients
ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), sintillimab plus SoC vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ORIENT-11, 2020 0.61 [0.40; 0.93]
0.61 [0.40 ; 0.93 ] ORIENT-11, 2020 1 0% 397 NA not evaluable progression or deaths (PFS)detailed results ORIENT-11, 2020 0.48 [0.36; 0.64]
0.48 [0.36 ; 0.64 ] ORIENT-11, 2020 1 0% 397 NA not evaluable objective responses (ORR)detailed results ORIENT-11, 2020 2.54 [1.63; 3.97]
2.54 [1.63 ; 3.97 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE (any grade)detailed results ORIENT-11, 2020 1.02 [0.03; 30.46]
1.02 [0.03 ; 30.46 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE (grade 3-4)detailed results ORIENT-11, 2020 1.13 [0.74; 1.73]
1.13 [0.74 ; 1.73 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE leading to death (grade 5)detailed results ORIENT-11, 2020 0.31 [0.11; 0.90]
0.31 [0.11 ; 0.90 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ORIENT-11, 2020 0.70 [0.31; 1.55]
0.70 [0.31 ; 1.55 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results ORIENT-11, 2020 0.64 [0.26; 1.56]
0.64 [0.26 ; 1.56 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Increase AST TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.98 [0.09; 10.96]
0.98 [0.09 ; 10.96 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Rash TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.16 [0.02; 1.56]
0.16 [0.02 ; 1.56 ] ORIENT-11, 2020 1 0% 397 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:40 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 874